scholarly journals EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma

1995 ◽  
Vol 71 (2) ◽  
pp. 371-375 ◽  
Author(s):  
PHM De Mulder ◽  
◽  
G Oosterhof ◽  
C Bouffioux ◽  
AT van Oosterom ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Interferon Alpha ◽  
Renal Cell ◽  
Phase Iii ◽  
Advanced Renal Cell Carcinoma ◽  
Recombinant Interferon ◽  
Phase Iii Study ◽  
Recombinant Interferon Alpha

Recombinant interferon alpha-2 in advanced renal cell carcinoma

1992 ◽  
Vol 59 (3) ◽  
pp. 74-77 ◽  
Author(s):  
A. Cozzoli ◽  
S. Cosciani Cunico
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Interferon Alpha ◽  
Renal Cell ◽  
Residual Disease ◽  
Advanced Renal Cell Carcinoma ◽  
Complete Regression ◽  
Recombinant Interferon ◽  
Retroperitoneal Node ◽  
Recombinant Interferon Alpha

From January 1985 to December 1987, 26 patients (20 men, 6 women, median age 62 years, range 26–76 years) with advanced renal cell carcinoma were included in the study. In 8 cases (6 patients no surgery, 2 patients with retroperitoneal node-residual disease after nephrectomy) metastases were identified at initial diagnosis, and in the remaining 18 the occurrence of metastases was delayed by a mean disease-free interval of 12 months after radical nephrectomy. Recombinant interferon alpha-2 was administered subcutaneously at a dose of 9 milion IU three times a week for a period of at least six months. Informed consent was obtained from all patients before starting therapy. No patients achieved complete regression of tumors; two cases showed a partial response (one relapsed six months later, while in the other response continues at 38 months after discontinuation of therapy); 10 patients showed stabilization of disease for 6–10 months and in 14 the disease progressed immediately. In our experience immunotherapy with recombinant interferon alpha-2 did not significantly change the natural history of renal cell carcinoma.

Phase II Study of Recombinant Interferon Alpha-2A and Vinblastine in Advanced Renal Cell Carcinoma

1989 ◽  
Vol 142 (2 Part 1) ◽  
pp. 253-256 ◽  
Author(s):  
Jan H. Schornagel ◽  
Jaap Verweij ◽  
Wim W. Ten Bokkel Huinink ◽  
Jan G.M. Klijn ◽  
Pieter H.M. De Mulder ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Interferon Alpha ◽  
Phase Ii ◽  
Renal Cell ◽  
Phase Ii Study ◽  
Advanced Renal Cell Carcinoma ◽  
Recombinant Interferon ◽  
Recombinant Interferon Alpha
Sign in / Sign up

Export Citation Format

Share Document